Lotte Biologics announced on the 22nd that it has completed construction of the main facilities at Plant 1 of its Incheon Songdo Bio Campus and obtained approval for use.

The plant has the capacity to produce a total of 120,000 L of antibody therapeutics. “Approval for use” means that not only the building and civil engineering works, but also key facilities required for plant operation—such as production equipment and piping, as well as electrical and control systems—have all been established. This outcome comes about two years after construction began in 2024. Lotte Biologics stated, “Given the complexity of cell culture processes and the characteristics of biopharmaceutical manufacturing facilities, this represents one of the fastest project execution speeds in the global industry.”

The Songdo Plant 1 is equipped with eight 15,000 L stainless steel bioreactors (equipment used to culture cells that become the raw material for pharmaceuticals), suitable for large-scale production. It has adopted the latest process technologies and introduced an automated logistics warehouse to streamline the movement of raw materials and products.

Lotte Biologics is expected to further accelerate its push into the global contract development and manufacturing organization (CDMO) market by linking the facility with its existing Syracuse Bio Campus in the United States. Under this structure, the Syracuse campus will handle early development and clinical production, while the Songdo plant will be responsible for large-scale commercial manufacturing.

Park James, CEO of Lotte Biologics, stated, “Based on a global production platform connecting Syracuse in the United States and Songdo in Incheon, the company will become a CDMO partner that customers can trust.”

Popular News